Pearce IP and its founder Naomi Pearce are ranked in the 2026 edition of Doyle’s Guide amongst a small number of leading NSW IP litigation firms and litigators. Naomi Pearce is one of 32 lawyers commended as NSW’s Leading Contentious Intellectual Property Lawyers.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 1 May 2026 are set out below…
On 9 February 2024, AU Pharma Pty Ltd filed a request for re-examination of the granted claims of Grunenthal’s AU2008241013 patent relating to titration methods of tapentadol. Tapentadol is a centrally acting analgesic known to be effective for the treatment of moderate to severe acute or chronic pain.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 24 April 2026 are set out below…
Cipla has defeated Teva’s and Bayer’s opposition to its application for an extension of time in which to pay the renewal fee on AU2003244799 for a combination of azelastine and steroids (the Cipla Patent), a combination used in the treatment of hay fever.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 17 April 2026 are set out below…
Helen Macpherson, Pearce IP’s Executive Lawyer and Head of Litigation (Australia), has been recognised in 2027 The Best Lawyers in Australia™ for Intellectual Property Law and Life Sciences. Helen has been listed by Best Lawyers every year since 2017.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the fortnight ending 10 April 2026 are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 27 March 2026 are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 20 March 2026 are set out below…
IP Australia Proposes Changes to “Streamline and Simplify” Australia’s IP System. Earlier this month IP Australia issued a consultation paper seeking submissions on proposed reforms primarily to Australia’s current IP system. The consultation paper has been developed in conjunction with New Zealand Ministry of Business…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 13 March 2026 are set out below…
The One That Got Away – Aussie Fashion Designer Wins Trade Mark Stoush Against Katy Perry. The battle of the KATY(IE) PERRY trade marks has been ongoing since 2019, but thankfully the High Court of Australia has now settled the issue once and for all. In a decision handed down yesterday (11 March 2026)…
BREAKING NEWS: The High Court of Australia today granted special leave to Otsuka to appeal the decision of the Full Federal Court in Otsuka v Sun Pharma [2025] FCAFC 161 in which it unanimously held that pharmaceutical formulation patents are ineligible for patent term extension (PTE) in Australia.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 6 March 2026 are set out below…
FORXIGA® Injunction Breaks New Ground. As we have previously reported, Justice Downes of the Federal Court of Australia has set a new record for expedition in the patent dispute between AstraZeneca and Pharmacor, relating to the latter’s generic dapagliflozin.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 27 February 2026 are set out below…
HOT TOPIC | A Seismic Shift in Australian Pharma Patent Strategy | Fault Lines Emerge in PTEs and Preliminary Injunctions. Recent developments in Australian law and practice concerning Patent Term Extensions (PTEs) and preliminary injunctions (PIs) will shake up the pharmaceutical market. For originators, generics and biosimilar sponsors alike…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 20 February 2026 are set out below…
In this 60 minute Masterclass, a panel of expert senior Pearce IP lawyers and patent attorneys discuss changes and A Seismic Shift in Pharma Patent Law & Practice in Australia. Do Recent Developments in PTEs & PIs Create New Strategic Opportunities to Disrupt the Pharma Market?
Out With The In-Crowd – Gene Therapy For A Previously Excluded, Antibody-Positive Patient Group Ruled Non-Inventive. The Australian Patent Office has refused to grant a patent on Australian Patent Application 2018299865 in the name of uniQure IP B.V.
Lack of clarity sends patent claims down the drain – All Valve Industries Pty Ltd & Anor V Comino & Anor. In this article, we report on a Federal Court judgment in which Justice Halley determined two proceedings with a number of claims and cross-claims invoking statute, common law and equity.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 13 February 2026 are set out below…
WTR1000 2026 | Pearce IP “Shaking the Trans-Tasman Market”. Pearce IP, and 5 of its Executives, in Australia and New Zealand have been ranked in WTR 1000 2026 for trade marks: Litigation and Prosecution & Strategy. WTR 1000 was glowing in its commentary of Pearce IP…
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
